Metastatic Disease Clinical Trial
Official title:
Abemaciclib Combined With Endocrine Therapy or as a Single Agent for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia. Prospective, Multicentre, Non-interventional, Observational Study.
The ATLANT study is prospective, multicentre, non-interventional, observational study. Patients with HR+/HER2-negative metastatic breast cancer received abemaciclib as monotherapy or in combination with endocrine therapy.
The ATLANT study is prospective, multicentre, non-interventional, observational study. 136 patients with HR+/HER2-negative metastatic breast cancer received abemaciclib as monotherapy or in combination with endocrine therapy in different line therapy. The purpose of this study is to better understand how abemciclib combinations are used in real-life conditions and their clinical impact for the treatment of Russian patients affected by (HR+)/ (HER2-) advanced breast cancer (ABC) or metastatic breast cancer (MBC). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01450683 -
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy
|
Phase 2 | |
| Terminated |
NCT04116164 -
Safety and Targeting of Anti-hk2 Antibody in mCRPC
|
Early Phase 1 | |
| Completed |
NCT04595032 -
MAnagement of METastatic Disease In Campania (MAMETIC)
|
||
| Terminated |
NCT01020305 -
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02496832 -
A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo
|
N/A | |
| Completed |
NCT01763970 -
Stereotactic Radiation Therapy for Pediatric Sarcomas
|
N/A | |
| Completed |
NCT01703910 -
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
|
Phase 2 | |
| Completed |
NCT00609401 -
Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)
|
Phase 2 | |
| Completed |
NCT02628379 -
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
|
||
| Completed |
NCT00480389 -
Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal
|
Phase 2 | |
| Recruiting |
NCT03632005 -
Negative Pressure Wound Therapy vs. Sterile Dressing for Patients Undergoing Thoracolumbar Spine Surgery
|
N/A | |
| Recruiting |
NCT04492735 -
The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
|
||
| Terminated |
NCT02175654 -
Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab
|
Phase 2 | |
| Not yet recruiting |
NCT01861938 -
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT01875380 -
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
| Terminated |
NCT00532454 -
Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen
|
Phase 2 | |
| Terminated |
NCT02795819 -
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
|
Phase 1 | |
| Recruiting |
NCT05188911 -
Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
|
||
| Completed |
NCT03823989 -
Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients
|
Phase 1 | |
| Terminated |
NCT01904916 -
CPCT-05 Biopsy Protocol Patient Selection
|
N/A |